Author:
Atsavapranee Ella,Haley Rebecca M.,Billingsley Margaret M.,Chan Alexander,Ruan Biao,Figueroa-Espada Christian G.,Gong Ningqiang,Mukalel Alvin J.,Bryan Philip N.,Mitchell Michael J.
Reference46 articles.
1. RAS proteins and their regulators in human disease;Simanshu;Cell,2017
2. The frequency of ras mutations in cancer;Prior;Cancer Res.,2020
3. RAS-mediated oncogenic signaling pathways in human malignancies;Khan;Semin. Cancer Biol.,2019
4. Drugging the undruggable RAS: Mission possible?;Cox;Nat. Rev. Drug Discov.,2014
5. FDA D.I.S.C.O. Burst Edition: FDA Approvals of Lumakras (Sotorasib) for Patients with KRAS G12C Mutated Locally Advanced or Metastatic Non-small Cell Lung cancer, and Truseltiq (Infigratinib) for Unresectable Locally Advanced or Metastatic Cholangiocarcin. (2021).